Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveThe base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) BioPharma Dive The base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study. Cardiovascular Read full story Post navigation Previous: Eli Lilly to buy trio of vaccine developers in $3.8bn outlayNext: FDA delays verdict on AZ breast cancer drug Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
